Neuroprotective Effects of a Novel Demeclocycline Derivative Lacking Antibiotic Activity: From a Hit to a Promising Lead Compound.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
04 09 2022
Historique:
received: 28 07 2022
revised: 29 08 2022
accepted: 30 08 2022
entrez: 9 9 2022
pubmed: 10 9 2022
medline: 14 9 2022
Statut: epublish

Résumé

The antibiotic tetracycline demeclocycline (DMC) was recently reported to rescue α-synuclein (α-Syn) fibril-induced pathology. However, the antimicrobial activity of DMC precludes its potential use in long-term neuroprotective treatments. Here, we synthesized a doubly reduced DMC (DDMC) derivative with residual antibiotic activity and improved neuroprotective effects. The molecule was obtained by removal the dimethylamino substituent at position 4 and the reduction of the hydroxyl group at position 12a on ring A of DMC. The modifications strongly diminished its antibiotic activity against Gram-positive and Gram-negative bacteria. Moreover, this compound preserved the low toxicity of DMC in dopaminergic cell lines while improving its ability to interfere with α-Syn amyloid-like aggregation, showing the highest effectiveness of all tetracyclines tested. Likewise, DDMC demonstrated the ability to reduce seeding induced by the exogenous addition of α-Syn preformed fibrils (α-Syn

Identifiants

pubmed: 36078167
pii: cells11172759
doi: 10.3390/cells11172759
pmc: PMC9454755
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Neuroprotective Agents 0
Lead 2P299V784P
Demeclocycline 5R5W9ICI6O

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

JAC Antimicrob Resist. 2022 Feb 15;4(1):dlac009
pubmed: 35198979
J Biol Chem. 2017 Aug 11;292(32):13482-13497
pubmed: 28611062
Clin Neuropharmacol. 2008 May-Jun;31(3):141-50
pubmed: 18520981
Mol Neurobiol. 2022 Feb;59(2):1273-1284
pubmed: 34984585
Nat Neurosci. 2020 Jan;23(1):21-31
pubmed: 31792467
Brain. 2013 Apr;136(Pt 4):1128-38
pubmed: 23466394
Int J Antimicrob Agents. 2003 Apr;21(4):364-91
pubmed: 12672587
PLoS One. 2013;8(2):e57827
pubmed: 23469077
Front Immunol. 2020 Feb 21;11:272
pubmed: 32153581
Neurosci Lett. 2019 Sep 14;709:134316
pubmed: 31170426
J Am Acad Dermatol. 2006 Feb;54(2):258-65
pubmed: 16443056
Biomed Pharmacother. 2022 May;149:112803
pubmed: 35286967
NPJ Parkinsons Dis. 2021 Jun 28;7(1):52
pubmed: 34183676
Biochim Biophys Acta. 2010 Jul;1804(7):1405-12
pubmed: 20399286
Sci Rep. 2020 Nov 20;10(1):20258
pubmed: 33219264
Angew Chem Int Ed Engl. 2020 May 18;59(21):8104-8107
pubmed: 32073233
Science. 2012 Nov 16;338(6109):949-53
pubmed: 23161999
Neurotherapeutics. 2021 Jul;18(3):1692-1709
pubmed: 34258749
Nat Chem Biol. 2021 Jun;17(6):653-664
pubmed: 34035513
Sci Rep. 2017 Feb 03;7:41755
pubmed: 28155912
Prog Neurobiol. 2018 Mar;162:17-36
pubmed: 29241812
J Chem Biol. 2010 Mar;3(1):1-18
pubmed: 19693614
Sci Rep. 2017 Aug 9;7(1):7690
pubmed: 28794446
Proc Natl Acad Sci U S A. 2008 Jun 24;105(25):8637-42
pubmed: 18550842
J Exp Med. 2012 May 7;209(5):975-86
pubmed: 22508839
Chem Commun (Camb). 2018 Aug 2;54(63):8667-8684
pubmed: 29978862
J Biol Chem. 2013 May 24;288(21):15194-210
pubmed: 23532841
Antibiotics (Basel). 2012 Jun 12;1(1):1-13
pubmed: 27029415
J Mov Disord. 2020 Jan;13(1):77-79
pubmed: 31601084
J Biol Chem. 2011 Jan 21;286(3):2121-31
pubmed: 21068391
J Immunol Methods. 1983 Dec 16;65(1-2):55-63
pubmed: 6606682
FEBS J. 2005 Dec;272(23):5962-70
pubmed: 16302961
JAMA Neurol. 2016 May 1;73(5):529-34
pubmed: 26999031
Protein Sci. 1993 Mar;2(3):404-10
pubmed: 8453378
Sci Adv. 2022 Feb 11;8(6):eabm6393
pubmed: 35138901
Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14669-74
pubmed: 11724929
J Mol Biol. 1997 Oct 31;273(3):729-39
pubmed: 9356260
BMC Bioinformatics. 2021 Sep 10;22(1):433
pubmed: 34507520
Cells. 2019 Jul 25;8(8):
pubmed: 31349736
Front Aging Neurosci. 2021 Mar 22;13:635760
pubmed: 33828477
Autophagy. 2016;12(1):1-222
pubmed: 26799652
J Mol Biol. 2002 Sep 13;322(2):383-93
pubmed: 12217698
Nat Protoc. 2014 Sep;9(9):2135-46
pubmed: 25122523
Methods Enzymol. 1999;309:285-305
pubmed: 10507031
Proc Natl Acad Sci U S A. 2009 Nov 24;106(47):20051-6
pubmed: 19892735
PLoS One. 2012;7(11):e48672
pubmed: 23144925
Mol Neurobiol. 2020 Apr;57(4):1889-1903
pubmed: 31879858
J Neurosci. 2002 Mar 1;22(5):1763-71
pubmed: 11880505
Cold Spring Harb Perspect Biol. 2020 Mar 2;12(3):
pubmed: 30936119
Neurotox Res. 2016 May;29(4):447-59
pubmed: 26745968
Nature. 2020 Sep;585(7825):464-469
pubmed: 32461689
Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15769-74
pubmed: 9861045
J Neurosci. 2017 Oct 11;37(41):9808-9818
pubmed: 29021298
Neuron. 2022 Mar 16;110(6):935-966
pubmed: 35134347
Cell Chem Biol. 2018 Nov 15;25(11):1389-1402.e9
pubmed: 30197194

Auteurs

Rodrigo Tomas-Grau (R)

Instituto de Investigación en Medicina Molecular y Celular Aplicada (IMMCA) (CONICET-UNT-SIPROSA), Pasaje Dorrego 1080, San Miguel de Tucumán 4000, Argentina.

Florencia González-Lizárraga (F)

Instituto de Investigación en Medicina Molecular y Celular Aplicada (IMMCA) (CONICET-UNT-SIPROSA), Pasaje Dorrego 1080, San Miguel de Tucumán 4000, Argentina.

Diego Ploper (D)

Instituto de Investigación en Medicina Molecular y Celular Aplicada (IMMCA) (CONICET-UNT-SIPROSA), Pasaje Dorrego 1080, San Miguel de Tucumán 4000, Argentina.

César L Avila (CL)

Instituto de Investigación en Medicina Molecular y Celular Aplicada (IMMCA) (CONICET-UNT-SIPROSA), Pasaje Dorrego 1080, San Miguel de Tucumán 4000, Argentina.

Sergio B Socías (SB)

Instituto de Investigación en Medicina Molecular y Celular Aplicada (IMMCA) (CONICET-UNT-SIPROSA), Pasaje Dorrego 1080, San Miguel de Tucumán 4000, Argentina.

Pierre Besnault (P)

Paris Brain Institute-ICM, Inserm, CNRS, Sorbonne Université APHP, Hôpital de la Pitié la Pitié-Salpêtrière, 75013 Paris, France.

Aurore Tourville (A)

Paris Brain Institute-ICM, Inserm, CNRS, Sorbonne Université APHP, Hôpital de la Pitié la Pitié-Salpêtrière, 75013 Paris, France.

Rosa M Mella (RM)

Innoprot SL, Parque Tecnológico de Bizkaia, Edificio 502, 48160 Derio, Spain.

Patricia Villacé (P)

Innoprot SL, Parque Tecnológico de Bizkaia, Edificio 502, 48160 Derio, Spain.

Clarisa Salado (C)

Innoprot SL, Parque Tecnológico de Bizkaia, Edificio 502, 48160 Derio, Spain.

Clémence Rose (C)

BioCIS, Université Paris-Saclay, CNRS, 92290 Châtenay-Malabry, France.

Blandine Seon-Méniel (B)

BioCIS, Université Paris-Saclay, CNRS, 92290 Châtenay-Malabry, France.

Jean-Michel Brunel (JM)

UMR_MD1 "Membranes et Cibles Thérapeutiques", U1261 INSERM, Aix-Marseille Université, 13385 Marseille, France.

Laurent Ferrié (L)

BioCIS, Université Paris-Saclay, CNRS, 92290 Châtenay-Malabry, France.

Rita Raisman-Vozari (R)

Paris Brain Institute-ICM, Inserm, CNRS, Sorbonne Université APHP, Hôpital de la Pitié la Pitié-Salpêtrière, 75013 Paris, France.

Patrick P Michel (PP)

Paris Brain Institute-ICM, Inserm, CNRS, Sorbonne Université APHP, Hôpital de la Pitié la Pitié-Salpêtrière, 75013 Paris, France.

Bruno Figadère (B)

BioCIS, Université Paris-Saclay, CNRS, 92290 Châtenay-Malabry, France.

Rosana Chehín (R)

Instituto de Investigación en Medicina Molecular y Celular Aplicada (IMMCA) (CONICET-UNT-SIPROSA), Pasaje Dorrego 1080, San Miguel de Tucumán 4000, Argentina.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH